pramlintide acetate

FDA Drug Profile — SymlinPen

Drug Details

Generic Name
pramlintide acetate
Brand Names
SymlinPen
Application Number
NDA021332
Sponsor
AstraZeneca Pharmaceuticals LP
NDC Codes
2
Dosage Forms
INJECTION
Routes
SUBCUTANEOUS
Active Ingredients
PRAMLINTIDE ACETATE

Indications and Usage

1 INDICATIONS AND USAGE SYMLIN is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy. SYMLIN is an amylin analog indicated for patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy (1) .